Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.

Brittany WippelKenneth R GundleTheresa DangJillian PaxtonJoseph BubaloLinda StorkRongwei FuChristopher W RyanLara E Davis

Published in: Cancer medicine (2018)

Age over 18 years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.

Keyphrases

high dose
young adults
stem cell transplantation
low dose
oxidative stress
human health
physical activity
risk assessment
childhood cancer
oxide nanoparticles
climate change